| Trial ID: | L2164 |
| Source ID: | NCT00952991
|
| Associated Drug: |
Laf237 = Vildagliptin
|
| Title: |
The Effects of LAF237 on Gastric Function in Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Non-Insulin-Dependent
|
| Interventions: |
DRUG: LAF237 = vildagliptin
|
| Outcome Measures: |
Primary: Gastric Emptying|Gastric accommodation|Satiety|Gastrointestinal Symptoms | Secondary: Meal Appearance Rate|Glucose Disappearance|Endogenous Glucose Production|Insulin Secretion|Glucagon Secretion
|
| Sponsor/Collaborators: |
Sponsor: Mayo Clinic | Collaborators: Novartis Pharmaceuticals
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
18
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE|Primary Purpose: TREATMENT
|
| Start Date: |
2005-05
|
| Completion Date: |
2006-02
|
| Results First Posted: |
|
| Last Update Posted: |
2011-03-23
|
| Locations: |
Mayo Clinic, Rochester, Minnesota, 55905, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00952991
|
